On Wednesday, PTC Therapeutics stock earned a positive adjustment to its Relative Strength (RS) Rating, from 66 to 77.
Can You Really Time The Stock Market?
This unique rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of over 80 as they launch their biggest price moves. See if PTC Therapeutics stock can continue to rebound and clear that threshold.
Is PTC Therapeutics Stock A Buy?
PTC Therapeutics stock is still inside a buying range after breaking past a 52.98 buy point in a consolidation. Once a stock moves 5% or higher beyond the initial entry, it's considered extended and out of buy range.
The biotech company posted 0% earnings growth in its most recent report. Sales rose -4%.
PTC Therapeutics stock holds the No. 116 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
